



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16551

Title: Chemotherapy beyond second-line in advanced gastric cancer

Reviewer's code: 00039368

Reviewer's country: Estonia

Science editor: Ya-Juan Ma

Date sent for review: 2015-01-24 08:39

Date reviewed: 2015-02-11 21:53

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

This is a well written systematic review and meta-analysis paper concerning the impact of third-and subsequent lines of chemotherapy on survival and quality of life in patients with advanced gastric cancer. The authors give the extensive overview about the present outlook of the studies related to prospective phase III trials in the second-line treatment of gastric cancer and consider the importance to offer further chemotherapy for advanced gastric cancer. The authors have reviewed and analyzed a sufficient amount of literature (31 references). The review is supplied with one Table and one Figure. However, it would be useful to discuss also the influence of genetic factors and molecular characteristics of advanced gastric cancer on improvement of chemotherapy of cancer (e. g. The Cancer Genome Atlas Network authors. Comprehensive Molecular Characterization of Gastric Adenocarcinoma. Online July 23, 2014. DOI:10.1038/nature13480).



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16551

Title: Chemotherapy beyond second-line in advanced gastric cancer

Reviewer's code: 00001114

Reviewer's country: Japan

Science editor: Ya-Juan Ma

Date sent for review: 2015-01-24 08:39

Date reviewed: 2015-02-02 14:44

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This review entitles "Chemotherapy beyond second-line in advanced gastric cancer" is well-written and comprehensive review about this subject. I have one comment - I feel that discussion is a little redundant. Please shorten the discussion.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16551

Title: Chemotherapy beyond second-line in advanced gastric cancer

Reviewer's code: 00160226

Reviewer's country: China

Science editor: Ya-Juan Ma

Date sent for review: 2015-01-24 08:39

Date reviewed: 2015-02-03 11:30

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input checked="" type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The authors performed a literature review of the current status of chemotherapy beyond 2nd line in treatment of advanced gastric cancer. Major: 1) Personally, I believe that most of the drugs that are used as 3rd line or below are probably new drugs undergoing phase I/II studies so this is very subjected to institutional research etc. Perhaps the focus of the article could be on 2nd line therapy or beyond and this may be more useful for the average reader. 2) Unpublished data are best not used as these have not been subjected to peer-review and the accuracy of data is not known. 3) For Targeted therapy, I believe some institutions are using as 1st or 2nd line so perhaps these should be discussed under a separate heading Minor: 1) English language needs editing 2) Pls add a table on current 3rd line cytotoxic chemotherapy